Roche's new data on Vabysmo and Susvimo at ARVO 2026 highlights significant advancements in retinal therapies, potentially enhancing its competitive position in the ophthalmology market. The findings may influence treatment guidelines and market dynamics, necessitating close observation of competitor responses. Regulatory context from FDA (FDA AP — VABYSMO (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (0 high-relevance).